Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics Inc (GLYC)
:GLYC
Top Page
GlycoMimetics
(NASDAQ:GLYC)
37Underperform
GlycoMimetics (GLYC) vs. S&P 500 (SPY)
Market Cap
$17.01M
Dividend YieldN/A
Average Volume (3M)2.53M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-100.00%
EPS Growth-0.58%
CountryUS
Employees4
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.59
Shares Outstanding64,513,860
10 Day Avg. Volume235,428
30 Day Avg. Volume2,534,901
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1870.90
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
GlycoMimetics Business Overview & Revenue Model
Company DescriptionGlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases that involve abnormal carbohydrate interactions. Operating primarily in the biopharmaceutical sector, GlycoMimetics develops its proprietary drug candidates targeting cancer and inflammatory diseases. Its lead product candidates include uproleselan, an E-selectin antagonist for the treatment of acute myeloid leukemia (AML), and other drugs in earlier stages of development.
How the Company Makes MoneyGlycoMimetics generates revenue primarily through research and development collaborations, milestone payments, and licensing agreements with larger pharmaceutical companies. These partnerships provide funding and resources for the development of its drug candidates. The company may also receive royalties from the commercial sales of any successfully developed products. As GlycoMimetics is a clinical-stage company, it does not yet have products on the market and thus does not generate revenue from direct product sales. Instead, its financial performance depends heavily on its ability to secure and maintain strategic partnerships to advance its drug pipeline toward commercialization.
GlycoMimetics Financial Statement Overview
Summary
GlycoMimetics faces significant financial challenges with consistent losses and negative cash flows. While the company maintains a strong cash position, its inability to generate revenue and profitability poses a substantial risk. These financial difficulties may hinder long-term sustainability unless addressed with strategic improvements in revenue and cost management.Income Statement
The company has consistently struggled with profitability, with negative EBIT and EBITDA margins over the years. Revenue growth has been volatile and largely declining, which is a significant concern for future sustainability. The absence of revenue in the latest annual report highlights a critical lack of income generation capability.15
Very Negative
Balance Sheet
The balance sheet shows a strong cash position relative to its debt, with a negative net debt indicating more cash than debt. However, the consistent negative equity growth and high liabilities relative to revenue generation are concerning. The equity ratio appears stable but is overshadowed by operational struggles.45
Neutral
Cash Flow
Operating and free cash flows have been negative, indicating cash burn without sufficient revenue to offset it. The cash flow to net income ratios are unfavorable, reflecting poor cash generation capabilities. Despite significant capital on hand, the company's inability to turn cash flow positive is worrisome.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 10.00K | 74.92K | 1.16M | 10.16M | Gross Profit |
| 0.00 | 10.00K | -957.23K | 146.36K | 10.16M | EBIT |
| -40.04B | -39.28M | -47.40M | -63.45M | -51.51M | EBITDA |
| -40.04B | -39.12M | -47.20M | -63.18M | -51.24M | Net Income Common Stockholders |
| 0.00 | -36.90M | ― | -63.14M | -50.27M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 10.72B | 41.79M | 47.87M | 90.25M | 137.03M | Total Assets |
| 11.09B | 45.32M | 51.81M | 94.35M | 142.83M | Total Debt |
| 66.84M | 808.40K | 918.55K | 1.92M | 2.82M | Net Debt |
| -10.65M | -40.98M | -46.95M | -88.33M | -134.22M | Total Liabilities |
| 5.78B | 6.90M | 8.88M | 12.74M | 14.61M | Stockholders Equity |
| 5.31B | 38.41M | 42.93M | 81.60M | 128.22M |
| Cash Flow | Free Cash Flow | |||
| -31.11B | -34.90M | -46.54M | -57.50M | -39.31M | Operating Cash Flow |
| -31.10B | -34.88M | -46.46M | -57.49M | -39.24M | Investing Cash Flow |
| 20.03M | -21.39K | -84.19K | -14.94K | -68.51K | Financing Cash Flow |
| 5.40M | 28.82M | 4.16M | 10.72M | 18.14M |
GlycoMimetics Technical Analysis
Negative
0.26
Price Trends
0.27
Negative
0.29
Negative
0.25
Positive
Market Momentum
>-0.01
Positive
46.19
Neutral
48.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLYC, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.27, and above the 200-day MA of 0.25, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.19 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLYC.
GlycoMimetics Risk Analysis
GlycoMimetics disclosed 59 risk factors in its most recent earnings report. GlycoMimetics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlycoMimetics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $37.33B | 43.77 | 17.33% | ― | 78.01% | ― | |
67 Neutral | $7.41B | 32.02 | 19.71% | ― | 52.97% | ― | |
49 Neutral | $6.94B | 0.66 | -52.58% | 2.47% | 22.65% | 0.94% | |
42 Neutral | $104.73M | ― | -54.21% | ― | -78.55% | -0.92% | |
41 Neutral | $54.03M | ― | 41.08% | ― | -0.55% | 49.85% | |
40 Underperform | $930.10M | ― | -34.74% | ― | -36.72% | -64.37% | |
37 Underperform | $17.01M | ― | -173.25% | ― | -100.00% | -0.58% |
* Healthcare Sector Average
Performance Comparison
GLYC
GlycoMimetics
0.26
-2.59
-90.88%
SRPT
Sarepta Therapeutics
73.61
-54.64
-42.60%
FATE
Fate Therapeutics
0.90
-5.96
-86.88%
KPTI
Karyopharm Therapeutics
5.60
-15.25
-73.14%
XNCR
Xencor
12.95
-8.58
-39.85%
ARGX
Argenx Se
605.52
207.95
52.31%
GlycoMimetics Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -7.14% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.Highlights
Low Discontinuation Rate
The study had a low discontinuation rate of 3%, indicating good patient retention and adherence to the trial protocol.
Rich Data Set for Future Analysis
The study involved 388 patients with an unprecedented follow-up of over 3 years, providing a rich data set for further analysis and potential insights into AML treatment.
Commitment to Further Research
Despite the trial's primary endpoint not being met, GlycoMimetics remains committed to exploring uproleselan's potential in AML and plans to conduct a rigorous analysis of the data.
Ongoing Trials and Future Plans
The National Cancer Institute is sponsoring an ongoing Phase II/III trial evaluating uproleselan in newly diagnosed older patients with AML, and results will be shared when available.
Lowlights
Phase III Study Did Not Meet Primary Endpoint
The pivotal Phase III study of uproleselan did not achieve a statistically significant improvement in overall survival in the intent-to-treat population.
Unprecedented Control Group Survival
The control group showed a median overall survival of 12.3 months, which is unprecedented in relapsed/refractory AML trials, potentially affecting the study's outcomes.
Financial and Budgetary Concerns
The company is evaluating ways to reduce cash burn and is expected to report back to investors with a revised budget.
Company Guidance
During the Q1 2024 earnings call for GlycoMimetics, the management provided updates on the Phase III study of their lead drug candidate, uproleselan, which unfortunately did not achieve a statistically significant improvement in overall survival for patients with relapsed/refractory acute myeloid leukemia (AML). The trial involved 388 patients across 70 sites in 9 countries, with a median overall survival of 13 months for the uproleselan arm and 12.3 months for the placebo arm. Despite not meeting its primary endpoint, the study's unexpected control group survival rate of over one year is considered unprecedented in this setting. The company plans to conduct a comprehensive analysis of the data in collaboration with medical, statistical, and regulatory experts and intends to present findings at a future medical meeting. Additionally, GlycoMimetics highlighted ongoing studies, including a National Cancer Institute-sponsored Phase II/III trial, and mentioned efforts to manage cash burn and revise budget plans as they proceed with further analyses and discussions with the FDA.GlycoMimetics Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
GlycoMimetics Faces Leadership Changes Amid Board Resignations
Negative
Feb 25, 2025
On February 19, 2025, GlycoMimetics received a termination notice from Apollomics, ending their Collaboration and License Agreement effective January 2, 2020, which granted Apollomics rights to develop and commercialize uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau, and Taiwan. This termination, effective 90 days post-notice, relieves GlycoMimetics of any material obligations under the agreement. Additionally, on February 21, 2025, several directors, including the CEO and CFO, resigned from GlycoMimetics’ Board, with the CEO and CFO entering into separation and consulting agreements. These changes indicate a significant shift in the company’s leadership structure.
M&A TransactionsRegulatory Filings and Compliance
GlycoMimetics and Crescent Biopharma Announce Merger Plans
Neutral
Jan 13, 2025
GlycoMimetics and Crescent Biopharma have updated their investor presentation related to their proposed merger. This presentation highlights that the merger is not a solicitation for any securities transaction. GlycoMimetics plans to file relevant materials with the SEC, including a proxy statement, urging investors to review these documents carefully. Crescent Biopharma, launched by Paragon Therapeutics, focuses on advancing cancer therapies, particularly with its innovative pipeline for solid tumors. The merger and developments could potentially impact the oncology market and investors are advised to stay informed through regulatory filings.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.